Spotting pancreatic cancer early

Monday, 2 May, 2016
Pancreatic cancer is usually detected too late, leaving patients little hope of recovery. But this may be about to change. A Swedish SME has developed a blood test to help clinicians identify new cases earlier, and it intends to make this diagnostic capability available very soon. Clinical validation is under way in an EU-funded project.

The Immpact project, which focuses on the final stages of the development of the new blood test, was launched in June 2015 for a duration of two years. It is implemented by Swedish start-up Immunovia. “The objective is to carry out the studies and commercialisation activities that are needed to take our invention from a prototype to a test that is available to the public,” says CEO Mats Grahn.

Read more

Project: 
Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.
Project Acronym: 
IMMPACT
Article
#H2020